INNOVATING RECEPTOR-INDEPENDENT DRUG DELIVERY TECHNOLOGY FOR THE MOST AGGRESSIVE DISEASES
At the center of our approach is a cellular process that enables our delivery technology to be both disease and payload agnostic.
KEY PROPERTIES
SCALABLE
Approach allows expansion into various indications (oncology, neurodegenerative, inflammatory, and infectious diseases) |
À LA CARTE PAYLOAD SELECTION
Amenable to various types of cargo (small molecules, PROTACs, radioisotopes, siRNA) |
SITE-SPECIFIC CONJUGATION
Precise control over Drug-to-Protein ratio |
EVOLVING THE TREATMENT PARADIGM FOR RAS-ACTIVATED CANCERS
|
Vertical Divider
|
Combining well-defined disease biology with clinically-validated payloads, our delivery platform holds much promise for the field of cancer therapeutics. It offers a clear pathway to create safe and effective therapeutics for the most recalcitrant cancers.
RAS CANCERS AT A GLANCE
● RAS mutations drive 1 in 5 cancer diagnoses in the United States, but there are limited treatment options for these tumors
● RAS-activated cancer growth is largely fueled by macropinocytosis, a cellular process that facilitates the bulk internalization of extracellular material
● Our novel drug approach exploits macropinocytosis to deliver a toxic payload to cancer cells, while avoiding healthy cells
● RAS-activated cancer growth is largely fueled by macropinocytosis, a cellular process that facilitates the bulk internalization of extracellular material
● Our novel drug approach exploits macropinocytosis to deliver a toxic payload to cancer cells, while avoiding healthy cells
A BETTER WAY FORWARD
Tezcat has developed a novel protein-drug conjugate that exploits the macropinocytosis process to deliver a toxic payload to cancer cells. Tezcat’s breakthrough therapy combines a carrier protein with a toxic payload, which is internalized by the cancer cells during macropinocytosis.
Cancer cells experiencing high levels of macropinocytosis “eat” the toxic payload and are destroyed in the process. At the same time, healthy cells do not exhibit macropinocytosis, so the toxic payload is not “eaten” by these cells, and they are not harmed in the process.
|
PARTNERING INQUIRIES
Beyond oncology, we recognize the vast potential of our technology and one of our goals is to develop innovative new therapeutics that exploit our drug delivery technology through creative academic and industry collaborations. If you are interested in exploring opportunities, please contact us below.
CONTACT US
|
BioLabs @NYULangone
180 Varick St, Fl 6 New York, NY 10014 District New Haven
470 James Street, Suite 007 New Haven, CT 06513 |